Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: Analysis of the correlations between in vitro test results and clinical response

Diagnostic Microbiology and Infectious Disease

Volumn 28, Issue 1, 1997, Pages 5-18

  Jones, Ronald N ^a   Dudley, Michael N ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c Microcide Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; SULTAMICILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MIXTURE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STANDARDIZATION;

AMPICILLIN; ANIMALS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTICENTER STUDIES; QUALITY CONTROL; RETROSPECTIVE STUDIES; SULBACTAM; TREATMENT OUTCOME;

EID: 0030797608     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00013-8     Document Type: Article

References (31)

1. Alexov M, Lister PD, Sanders CC (1996) Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: Sulbactam pharmacokinetics in pharmacodynamic interactions. Antimicrob Agents Chemother 40:2468-2477.
2. Baron EJ, Jones RN (1995) National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. Diagn Microbiol Infect Dis 21:141-151.
3. Barry AL, Jones RN, Thornsberry C (1984) Interpretive standards and quality control limits for susceptibility tests with ampicillin/sulbactam combination disks. J Clin Microbiol 19:134-139.
4. Bush K (1989) Characterization of β-lactamases; Groups 1, 2a, 2b and 2c. Antimicrob Agents Chemother 33:264-270.
5. Bush K, Jacoby GA, Medeiros AA (1995) A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:1211-1233.
6. Craig WA (1995) Activity of ampicillin/sulbactam with simulation of human pharmacokinetics in an animal model. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, (asbt A 61).
7. Domst J, Sadler J, Yassien M, Khardori N (1994) In vitro susceptibility of 248 recent clinical isolates of Escherichia coli to ampicillin/sulbactam 10 μg/10 μg and 20 μg/20 μg disks. In Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, (abst E 50).
8. Firsov AA, Savarino D, Ruble M, Gilbert D, Manzano B, Medeiros AA, Zinner SH (1996) Predictors of effect of ampicillin/sulbactam against TEM-1 β-lactamase-producing Escherichia coli in an in vitro dynamic model: Enzyme activity versus MIC. Antimicrob Agents Chemother 40:734-738.
9. Foulds G (1986) Pharmacokinetics of sulbactam/ampicillin in humans: A review. Rev Infect Dis 8(suppl 5):S503-S511.
10. Isenberg HD, Alperstein P, France K (1997) Response of enteric Gram-negative bacteria to disks containing 20 micrograms each of ampicillin and sulbactam. J Clin Microbiol 35:523-524.
11. Jenkins SG (1992) Antimicrobial susceptibility tests for beta-lactam/beta-lactamase inhibitors: Predictors of clinical efficacy? Clin Microbiol Newslett 14:89-93.
12. Jochimsen WG, Sheehan DJ, Mylott G (1995) Ampicillin/sulbactam (A/S): Correlation between in vitro antimicrobial susceptibility testing and clinical activity. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, (abst C 114).
13. Jones RN (1988) In vitro evaluations of aminopenicillin/β-lactamase inhibitor combinations. Drugs 35(suppl 7):17-26.
14. Jones RN, Barry AL (1987) Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin/sulbactam combination. J Clin Microbiol 25:1920-1925.
15. Lamp KC, Vickers MK (1994) Pharmacodynamics of ampicillin/sulbactam in an in vitro infection model against increasingly resistant Escherichia coli. In Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology.
16. Lees L, Milson JA, Knirsch AK, Greenhalgh K (1986) Sulbactam plus ampicillin: Interim review of efficacy and safety for therapeutic and prophylactic use. Rev Infect Dis 8(suppl 5):S644-S650.
17. Lederle Laboratories (1994) Data on file.
18. Lister PD, Sanders CC (1995) Comparison of ampicillin/sulbactam regimens simulating 1.5-and 3-gram doses in treatment of Escherichia coli bacteremia in mice. Antimicrob Agents Chemother 39:930-936.
19. Marshall SA, Aldridge KE, Allen SD, Fuchs PC, Gerlach EH, Jones RN (1995) Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. Diagn Microbiol Infect Dis 21:153.
20. Murray PR, Cantrell HF, Lankford RB (1994) Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected β-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis 19:111-120.
21. National Committee of Clinical Laboratory Standards (NCCLS) (1993a) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A3. 3rd edition. Villanova, PA: NCCLS.
22. National Committee of Clinical Laboratory Standards (NCCLS) (1993b) Performance standards for antimicrobial disk susceptibility tests: approved standards M2-A5. 5th edition. Villanova, PA: NCCLS.
23. National Committee of Clinical Laboratory Standards (NCCLS) (1994) Development of in vitro susceptibility testing criteria and quality control parameters: approved guideline M23-A. Villanova, PA:NCCLS.
24. Neu HC (1985) Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases. Am J Med 79(suppl 5B):2-12.
25. Pfizer, Inc. (1996) Data on file.
26. Philippon A, Arlet G, LaGrange PH (1994) Origin and impact of plasmid mediated extended-spectrum β-lactamases. Eur J Clin Microbiol Infect Dis (Suppl 1):17-29.
27. Timentin® (Ticarcillin/Clavulanic Acid) (1995) Clinical pharmacology. Philadelphia, PA: SmithKline Beecham (product package insert).
28. Retsema JA, English AR, Girard A, Lynch JE, Anderson M, Bernnan L, Cimochowsky C, Faiella J, Norcia W, Sawyer P (1986) Sulbactam/ampicillin: In vitro spectrum, potency, and activity in models of acute infection. Rev Infect Dis 8(suppl 5):S528-S534.
29. Richmond MH, Sykes RB (1973) The beta-lactamases of Gram-negative bacteria and their possible physiological role. Adv Microb Physical 9:31-38.
30. Scully BE, Clin N-X, Neu HC (1985) Pharmacology of ticarcillin combined with clavulanic acid in humans. Am J Med 79(suppl 5B):39-43.
31. Valcke YJ, Rosseel MT, Pauwels RA, Bogaert MG, Van der Straeten ME (1990) Penetration of ampicillin and sulbactam in the lower airways during respiratory infections. Antimicrob Agents Chemother 34:958-962.